tiprankstipranks
Vanda Pharmaceuticals Inc. (CH:VM4)
:VM4
Switzerland Market
VM4
Vanda
RESEARCH TOOLSreports

Vanda (VM4) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

VM4 Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Vanda
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VM4 Stock 12 Month Forecast

Average Price Target

―
Based on 3 Wall Street analysts offering 12 month price targets for Vanda in the last 3 months. The average price target is CHF11.71 with a high forecast of CHF16.35 and a low forecast of CHF8.99. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF16.35Average Price TargetCHF11.71Lowest Price TargetCHF8.99
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:VM4
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
CHF17.16→CHF16.35
Buy
―
Reiterated
08/10/26
Vanda Pharmaceuticals price target lowered to $20 from $21 at H.C. WainwrightVanda Pharmaceuticals price target lowered to $20 from $21 at H.C. Wainwright
B. Riley Securities Analyst forecast on CH:VM4
Madison Elsaadi
B. Riley Securities
B. Riley Securities
CHF13.89→CHF9.81
Buy
―
Initiated
08/10/26
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO), Vanda (NASDAQ: VNDA) and AbCellera Biologics (NASDAQ: ABCL)
Cantor Fitzgerald Analyst forecast on CH:VM4
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
CHF8.99
Buy
―
Reiterated
08/06/26
Vanda (VNDA) Gets a Buy from Cantor Fitzgerald
Truist Financial Analyst forecast on CH:VM4
Les Sulewski
Truist Financial
Truist Financial
CHF14.71
Buy
―
Reiterated
05/07/26
Truist Financial Sticks to Its Buy Rating for Vanda (VNDA)
Jefferies Analyst forecast on CH:VM4
Andrew Tsai
Jefferies
Jefferies
CHF4.09→CHF6.13
Hold
―
Reiterated
12/31/25
Vanda Pharmaceuticals price target raised to $7.50 from $5 at JefferiesVanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:VM4
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
CHF17.16→CHF16.35
Buy
―
Reiterated
08/10/26
Vanda Pharmaceuticals price target lowered to $20 from $21 at H.C. WainwrightVanda Pharmaceuticals price target lowered to $20 from $21 at H.C. Wainwright
B. Riley Securities Analyst forecast on CH:VM4
Madison Elsaadi
B. Riley Securities
B. Riley Securities
CHF13.89→CHF9.81
Buy
―
Initiated
08/10/26
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO), Vanda (NASDAQ: VNDA) and AbCellera Biologics (NASDAQ: ABCL)
Cantor Fitzgerald Analyst forecast on CH:VM4
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
CHF8.99
Buy
―
Reiterated
08/06/26
Vanda (VNDA) Gets a Buy from Cantor Fitzgerald
Truist Financial Analyst forecast on CH:VM4
Les Sulewski
Truist Financial
Truist Financial
CHF14.71
Buy
―
Reiterated
05/07/26
Truist Financial Sticks to Its Buy Rating for Vanda (VNDA)
Jefferies Analyst forecast on CH:VM4
Andrew Tsai
Jefferies
Jefferies
CHF4.09→CHF6.13
Hold
―
Reiterated
12/31/25
Vanda Pharmaceuticals price target raised to $7.50 from $5 at JefferiesVanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARWRArrowhead Pharmaceuticals
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
AXGNAxoGen
HITIHigh Tide
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vanda

3 Months
Ram SelvarajuH.C. Wainwright
Success Rate
8/16 ratings generated profit
50%
Average Return
+10.36%
Copying Ram Selvaraju's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +10.36% per trade.
1 Year
Ram SelvarajuH.C. Wainwright
Success Rate
8/16 ratings generated profit
50%
Average Return
+2.92%
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +2.92% per trade.
2 Years
Ram SelvarajuH.C. Wainwright
Success Rate
8/16 ratings generated profit
50%
Average Return
-6.17%
Copying Ram Selvaraju's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -6.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VM4 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
6
5
6
6
5
Buy
2
1
1
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
6
7
6
5
In the current month, VM4 has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. VM4 average Analyst price target in the past 3 months is 11.71.
Each month's total comprises the sum of three months' worth of ratings.

VM4 Financial Forecast

VM4 Earnings Forecast

Next quarter’s earnings estimate for VM4 is -CHF0.55 with a range of -CHF0.67 to -CHF0.47. The previous quarter’s EPS was -CHF0.84. VM4 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year VM4 has Performed in-line its overall industry.
Next quarter’s earnings estimate for VM4 is -CHF0.55 with a range of -CHF0.67 to -CHF0.47. The previous quarter’s EPS was -CHF0.84. VM4 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year VM4 has Performed in-line its overall industry.

VM4 Sales Forecast

Next quarter’s sales forecast for VM4 is CHF56.05M with a range of CHF49.17M to CHF61.79M. The previous quarter’s sales results were CHF40.87M. VM4 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year VM4 has Performed in-line its overall industry.
Next quarter’s sales forecast for VM4 is CHF56.05M with a range of CHF49.17M to CHF61.79M. The previous quarter’s sales results were CHF40.87M. VM4 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year VM4 has Performed in-line its overall industry.

VM4 Stock Forecast FAQ

What is CH:VM4’s average 12-month price target, according to analysts?
Based on analyst ratings, Vanda Pharmaceuticals Inc.’s 12-month average price target is 11.71.
    What is CH:VM4’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:VM4, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Vanda Pharmaceuticals Inc. a Buy, Sell or Hold?
        Vanda Pharmaceuticals Inc. has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Vanda Pharmaceuticals Inc.’s share price target?
          The average share price target for Vanda Pharmaceuticals Inc. is 11.71. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF16.35 ,and the lowest forecast is CHF8.99. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Vanda Pharmaceuticals Inc.?
            Vanda Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
              How can I buy shares of Vanda Pharmaceuticals Inc.?
              To buy shares of CH:VM4, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.